# LifeArc

> LifeArc is a VC fund in London backing Biotechnology and Health Care. See 19 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 19
- Last investment: Nov 2023
- Lead investor: 32%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/278071
- X (Twitter): https://www.twitter.com/lifearc1
- Website: https://www.lifearc.org/

LifeArc is an independent life science medical research charity committed to drastically improving positive patient outcomes everywhere. It specializes in the fields of biotechnology, healthcare, and medical. It was founded in 1992 and headquartered in London, England.

## Contacts

5 contacts available for LifeArc. Shizune tracks 3 team members at LifeArc. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/lifearc?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 53% |
| Health Care | 7 | 37% |
| Therapeutics | 5 | 26% |
| Pharmaceutical | 5 | 26% |
| Medical | 2 | 11% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 7 | 37% |
| Series A | 3 | 16% |
| Grant | 2 | 11% |
| Series B | 2 | 11% |
| Funding Round | 2 | 11% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 12 | 63% |
| United States | 2 | 11% |
| Sweden | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ian Campbell | Chief Business Officer (CBO) | 14 | https://shizune.co/investors/profile/ian-campbell-3106 |
| Melanie Lee | Founder & CEO | 0 | https://shizune.co/investors/profile/melanie-lee-dc72 |
| Paul Mussenden | Non-executive Deputy Chairman, Chair of Audit & Risk Management Committee | 0 | https://shizune.co/investors/profile/paul-mussenden |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| FunctionRx | FunctionRx is a biotechnology company developing therapies for neurodegeneration. |  | Seed | Nov 21, 2023 |  |
| OxCan | OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection. | $3.6M | Seed | Jan 10, 2023 |  |
| University of Manchester | The University of Manchester was formed in 2004 by the amalgamation of the Victoria University of Manchester and the University of Manchester Institute of Science and Technology. It is a member of the worldwide Universities Research Association group, the Russell Group of British research universities and the N8 Group. The University of Manchesterhas been a red brick university since 1880 when Victoria University gained its royal charter.The university owns and operates major cultural assets such as the Manchester Museum, Whitworth Art Gallery, John Rylands Library and Jodrell Bank Observatory. The University of Manchester has 25 Nobel Laureates among its past and present students and staff, the third-highest number of any single university in the United Kingdom after Cambridge and Oxford.According to The Sunday Times, Manchester has a formidable reputation spanning most disciplines, but most notably in the life sciences, engineering, humanities, economics, sociology and the social sciences. The 2013 Times Higher Education World Reputation Rankings have placed Manchester as the 9th most reputable university in Europe. | $3M | Grant | Jan 01, 2023 |  |
| AviadoBio | AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK DementiaResearch Institute. | $77.9M | Series A | Dec 02, 2021 |  |
| Closed Loop Medicine | Closed Loop Medicine is the global leader in the development of single prescription drug plus digital therapy (DTx) combination products developed to optimise dosing on an individual level with linked behaviour therapy to improve patient outcomes. The company was founded by an experienced team of healthcare professionals, entrepreneurs and lifescientists with experience of both drug and software development, as well as extensive health system innovation experience. The company has two products in development for hypertension and insomnia. It has further products in its pipeline for a wide portfolio of chronic diseases. The Company ensures that both patient and clinician are at the centre of its products design and development. | $16.6M | Series A | Nov 03, 2021 |  |
| Closed Loop Medicine | Closed Loop Medicine is the global leader in the development of single prescription drug plus digital therapy (DTx) combination products developed to optimise dosing on an individual level with linked behaviour therapy to improve patient outcomes. The company was founded by an experienced team of healthcare professionals, entrepreneurs and lifescientists with experience of both drug and software development, as well as extensive health system innovation experience. The company has two products in development for hypertension and insomnia. It has further products in its pipeline for a wide portfolio of chronic diseases. The Company ensures that both patient and clinician are at the centre of its products design and development. | $17.8M | Seed | Nov 03, 2021 |  |
| Climb Bio | Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders. The company leverages its expertise in neuroscience, translational medicine, and clinical development to meet this unmet medical need with a highly innovative pipeline.Eliem Therapeutics develops and commercializes potentially“best-in-class” drug candidates to treat neuronal excitability disorders. These conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. | $60M | Series B | May 24, 2021 |  |
| Cumulus Neuroscience | Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. | $8.3M | Venture - Series Unknown | May 04, 2021 |  |
| DJS Antibodies | DJS Antibodies is discovering game-changing medicines to address recognised unmet medical need. Discovering new medicines is extremely difficult and most traditional methods fail. They have a breakthrough technology which overcomes this hurdle – revolutionising drug development. Early work, funded by Johnson&Johnson, has shown an unprecedentedsuccess rate in discovering lead antibodies and has lead to the development of lead programmes in both cancer and kidney disease. | $7.9M |  | Dec 22, 2020 |  |
| DJS Antibodies | DJS Antibodies is discovering game-changing medicines to address recognised unmet medical need. Discovering new medicines is extremely difficult and most traditional methods fail. They have a breakthrough technology which overcomes this hurdle – revolutionising drug development. Early work, funded by Johnson&Johnson, has shown an unprecedentedsuccess rate in discovering lead antibodies and has lead to the development of lead programmes in both cancer and kidney disease. | $8M | Seed | Dec 22, 2020 |  |

10 of 19 investments shown.

## Co-investors
- [Dementia Discovery Fund](https://shizune.co/investors/profile/dementia-discovery) — VC Fund, 4 deals together
- [Advent Life Sciences](https://shizune.co/investors/profile/advent-life) — VC Fund, 2 deals together
- [Amgen Ventures](https://shizune.co/investors/profile/amgen-ventures) — VC Fund, 2 deals together
- [Ananda Impact Ventures](https://shizune.co/investors/profile/ananda-ventures-gmbh-social-venture-fund) — VC Fund, 2 deals together
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund, 2 deals together
- [Cambridge Angels group](https://shizune.co/investors/profile/cambridge-angels-group) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Biotech Investors in United Kingdom](https://shizune.co/investors/biotech-investors-united-kingdom)

## FAQ

### What does LifeArc invest in?

LifeArc invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 19 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact LifeArc?

Public channels for LifeArc include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at LifeArc?

The team at LifeArc includes Ian Campbell (Chief Business Officer (CBO)), Melanie Lee (Founder & CEO) and Paul Mussenden (Non-executive Deputy Chairman, Chair of Audit & Risk Management Committee). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co